CD274 and neoplasm: As a predictor of a patient’s response in advance of immunotherapy treatment, the standard IHC PD-L1 test (Agilent Technologies, CA, USA), based on protein levels of expression in the biopsy of the tumour, will deliver its result with an average accuracy of 40% [4].